Recursion Pharmaceuticals plans to acquire Exscientia, with shareholders controlling about 53% of Exscientia's shares agreeing to support the deal, pending necessary approvals.
AI Assistant
RECURSION PHARMACEUTICALS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.